CORDIS · 315717 · FP7
SPECCC Specialised Cell Carrier Components
Coordinator: CELLON SA (LU)
Silicone offers significant advantages as a 3D cell scaffold, essentially a 3D microtissue device. These benefits include a capacity for variable porosity, variable open pore volume for cell entrapment, variable density for fluidisation, variable geometry, friction resistance, and low toxicity. The lead SME partner Cellon SA holds the IP for porous silicone carriers (Immobasil), which met some of these criteria, but exhibited poor cell adherence and requires re-engineering and exploitation of current cell biology knowledge and applications. There is a strong commercial need for such fully fun…
About Seventh Framework Programme (2007–2013)
The Seventh Framework Programme (FP7) ran from 2007 to 2013 and was the EU's main research-funding instrument of that period. It mobilised roughly €50 billion across cooperation projects, ERC frontier grants, Marie Curie fellowships, capacity-building actions and Euratom research. FP7 closed to new calls in 2013 but its projects continued for years after under their original grant agreements.
Co-funding: the European Union contributes €1.1M toward a total project budget of €1.4M — a funding rate of 75%, with the remainder covered by the consortium partners. The project runs over approximately 8 years from 2012-11-01 to 2020-10-31.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu →More from LU
see all →- HEDGE-IoT — Holistic Approach towards Empowerment of the DiGitalization of the Energy Ecosystem through adoption of IoT solutions101136216 · HORIZON · €18.0M
- DESIDERATA — Integrated Pathways: Advancing Safe and Sustainable by Design Material Innovation through Collaborative Wisdom101178011 · HORIZON · €10.7M
- TrustChain — Fostering a Human-Centered, Trustworthy and Sustainable Internet101093274 · HORIZON · €10.6M
- HealthyW8 — Empowering healthy lifestyle behaviour through personalised intervention portfolios to prevent and control obesity during vulnerable stages of life101080645 · HORIZON · €10.0M
- PATH — Patient AI Treatment Hub101253520 · HORIZON · €8.9M
- ALCEMIST — Atypical Liquid Crystal Elastomers: from Materials Innovation to Scalable processing and Transformative applications101167171 · HORIZON · €8.5M
Other FP7 projects
see all →- COST II — Provision of Scientific, Technical and Administrative Management of COST200443 · FR · €250.0M
- COMBACTE-NET — Combatting Bacterial Resistance in Europe115523 · SE · €109.4M
- EUC²LID — European Lead Factory115489 · DE · €80.0M
- COMBACTE-MAGNET — Combatting Bacterial Resistance in Europe - Molecules against Gram Negative Infections115737 · SE · €75.3M
- ENABLE — European Gram Negative Antibacterial Engine115583 · UK · €58.9M
- PLACES2BE — Pilot Lines for Advanced CMOS EmbodimentS in 2x nodes, Built in Europe325633 · FR · €52.6M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Seventh Framework Programme (2007–2013) programme, under the BSG-SME funding scheme.
- What is the EU contribution?
- The European Commission contributes €1.1M toward a total project budget of €1.4M.
- Which EU programme funds it?
- The project is funded under Seventh Framework Programme (2007–2013).
- Who coordinates the project?
- The project is coordinated by CELLON SA (LU).
- What is the project timeline?
- The project runs from 2012-11-01 to 2020-10-31 — approximately 8 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 315717.